Key facts
- This page summarizes Andrew Toy's Form 4 filing for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Jul 2026, 16:59.
Andrew Toy - 15 Jul 2026 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CLOV
- Reported as of
- 15 Jul 2026
- Net transaction value
- -$292,860
- SEC form
- 4
- Accepted by SEC
- 16 Jul 2026, 16:59:19 UTC
- Prior SEC filing
- 01 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/Peter J. Rivas as attorney-in-fact for Andrew Toy
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Andrew Toy filed Form 4 for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) on 16 Jul 2026.
Change
- Previous filing in this sequence was filed on 01 Jul 2026.
- Current net transaction value: -$292,860.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001838733
Primary reporting owner
Toy Andrew
- Relationship
- Chief Executive Officer, Director
- Address
- C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON
- Signature
- /s/Peter J. Rivas as attorney-in-fact for Andrew Toy
- Signature date
- 16 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLOV
transaction
Class A Common Stock
Sale
- Transaction value
- $292,860
- Shares
- -62,711
- Change %
- -0.65%
- Price
- $4.67
- Shares after
- 9,547,114
- Date
- 15 Jul 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The sales reported on this Form 4 represent shares of Class A Common Stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6.25% of restricted stock units ("RSUs") originally granted to the Reporting Person on October 15, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Footnote F2
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.67 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.